EISAI CO., LTD. Inactive Instrument
Eisai Co., Ltd. Share Price OTC Markets
Equities
ESALY
US2825793092
Pharmaceuticals
| Sales 2025 * | 764B 4.75B 396B | Sales 2026 * | 841B 5.23B 436B | Capitalization | 1,852B 11.51B 960B |
|---|---|---|---|---|---|
| Net income 2025 * | 45.34B 282M 23.51B | Net income 2026 * | 62.72B 390M 32.52B | EV / Sales 2025 * | 2.17 x |
| Net cash position 2025 * | 195B 1.21B 101B | Net cash position 2026 * | 200B 1.25B 104B | EV / Sales 2026 * | 1.96 x |
| P/E ratio 2025 * |
40.8
x | P/E ratio 2026 * |
29.5
x | Employees | 11,067 |
| Yield 2025 * |
2.49% | Yield 2026 * |
2.59% | Free-Float | 93.85% |
More Fundamentals
* Assessed data
More news
Latest transcript on Eisai Co., Ltd.
More recommendations
More press releases
More news
| Managers | Title | Age | Since |
|---|---|---|---|
Haruo Naito
CEO | Chief Executive Officer | 76 | 01/75/01 |
Mitsuru Shomon
DFI | Director of Finance/CFO | - | - |
Keisuke Naito
COO | Chief Operating Officer | 35 | 01/13/01 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Haruo Naito
CEO | Chief Executive Officer | 76 | 01/75/01 |
Fumihiko Ike
BRD | Director/Board Member | 72 | 01/21/01 |
Toru Moriyama
BRD | Director/Board Member | 69 | - |
Eisai Company specializes in the manufacturing and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- pharmaceutical products (87.7%): prescribed drugs, health products, etc.;
- other (12.3%): food additives, chemical products, etc.
Net sales are distributed geographically as follows: Japan (46.2%), Europe (19.5%), Americas (15.5%), China (10.3%) and other (8.4%).
Sector
Pharmaceuticals
Calendar
06/11/2024
- Q2 2024 Earnings Release (Projected)
Related indices
| 1st Jan change | Capi. | |
|---|---|---|
| +56.92% | 809B | |
| +39.52% | 624B | |
| -7.16% | 351B | |
| +7.32% | 289B | |
| +13.74% | 240B | |
| +13.83% | 220B | |
| -0.49% | 219B | |
| +7.86% | 166B | |
| -2.48% | 157B |
